Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | Single-cell multiomics to study malignant megakaryocytes

Bethan Psaila • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms

Bethan Psaila, MBBS, MRCP, FRCPath, PhD, University of Oxford, Oxford, UK, discusses the future prospects of immunotherapy in myeloproliferative neoplams (MPNs), highlighting current research on novel targets that might selectively be expressed in the mutant clone of hematopoietic stem cells. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Bethan Psaila

1:27
Immunotherapy for MPNs: where do we stand?
Bethan Psaila • 15 Nov 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals